---
title: Genetic Determinants of Hemodynamic Response to Esmolol
nct_id: NCT01388036
overall_status: UNKNOWN
phase: NA
sponsor: Hadassah Medical Organization
study_type: INTERVENTIONAL
primary_condition: Decrease in Heart Rate Below Baseline Value
countries: Israel
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01388036.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01388036"
ct_last_update_post_date: 2011-07-06
last_seen_at: "2026-05-12T07:21:07.913Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Genetic Determinants of Hemodynamic Response to Esmolol

**Official Title:** A Study in Healthy Subjects to Evaluate Genetic Determinants of the Variability in Hemodynamic Response to Esmolol

**NCT ID:** [NCT01388036](https://clinicaltrials.gov/study/NCT01388036)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 100
- **Lead Sponsor:** Hadassah Medical Organization
- **Conditions:** Decrease in Heart Rate Below Baseline Value
- **Start Date:** 2011-07
- **CT.gov Last Update:** 2011-07-06

## Brief Summary

Beta 1 Adrenergic antagonists (beta blockers) have major role in the treatment of CHF, IHD and hypertension. However, there is large interindividual variability in the response to beta blockers.

The hypothesis underlying this study is that genetic differences between individuals will determine the individual response to esmolol, a betablocker that is administered intravenously. Esmolol will be administered intravenously to healthy volunteers, and the effects on heart rate and blood pressure will be monitored. In addition, we will measure plasma renin activity and plasma levels of norepinephrine.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 50 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* healthy male and female
* able to understand and sign informed consent

Exclusion Criteria:

* consumption of any medication
* bradycardia \<50 BPM
* hypersensitivity to beta blockers
```

## Arms

- **esmolol infusion** (EXPERIMENTAL) — infusion of esmolol during rest and exercise

## Interventions

- **esmolol** (DRUG) — consecutive infusions of esmolol and normal saline (placebo)

## Primary Outcomes

- **Change in heart rate during exercise** _(time frame: 3 hours)_ — continous measurement of heart rate

## Secondary Outcomes

- **change in systolic blood pressure during exercise** _(time frame: 3 hours)_

## Locations (1)

- Hadassah Hebrew University Medical Center, Jerusalem, Israel — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.hadassah hebrew university medical center|jerusalem||israel` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01388036.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01388036*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*